Interim Report 1 2025/26
MAY 2025 – JULY 2025
Net sales | 365 (1 338) KSEK |
Operating result before depreciation (EBITDA) | -7 048 (-4 733) KSEK |
Net result | -8 542 (-5 929) KSEK |
Earnings per share | -0,14 (-0,23) SEK |
Gross margin | 68 (83) % |
In Short
- The 21st of May Patrik Eschricht, former CEO of PHI came back as CEO.
- The 11th of July Altium A/S global distributor agreement was changed to a non-exclusivity agreement.
- The quarter’s sales have been affected by the change in sales strategy, from a global agreement with Altium A/S to direct sales from PHI to distributors.
CEO Commentary
The first quarter of the fiscal year marks a pivotal moment for PHI as we continue to build momentum across our strategic pillars. Our commitment to innovation, clinical integration, and global expansion remains steadfast, and the progress made this quarter reflects the dedication and ingenuity of our entire team.
We have made significant strides in the development of the new generation of the HoloMonitor® system, integrating AI-driven features that enhance data interpretation and automation. These advancements not only strengthen our product offering but also position PHI at the forefront of non-invasive cell analysis technologies.
Our efforts to deepen partnerships with clinical research centres and regulatory bodies are progressing well. These collaborations are essential as we move toward validating and certifying our systems for clinical use—an important step in expanding our impact within regenerative medicine and personalised healthcare.
PHI is again taking full control of its global sales operations as part of our strategic shift to accelerate international growth and strengthen customer engagement. We are also actively searching to enter new territories to expand our global footprint.
This transition, initiated during the summer months, a period traditionally marked by lower sales activity, was deliberately timed to minimize disruption. As a result, sales in the first quarter were temporarily impacted. However, this short-term dip reflects the structural change in sales strategy rather than underlying market demand.
Previously supported by Altium, a key investor and global distributor, PHI is now leveraging the foundation built through that partnership to independently drive market penetration and adoption of the HoloMonitor® system. By internalizing global sales, PHI gains greater control over its commercial strategy, enabling more targeted outreach, improved cash flow, and stronger alignment with its innovation roadmap.
This strategic move allows us to focus on our core strengths, advancing quantitative phase imaging (QPI) technology and developing cutting-edge solutions for regenerative medicine, while positioning PHI as a more agile and globally integrated player in the live-cell imaging market.
Future Outlook
Looking ahead, PHI is strategically positioned at the intersection of imaging technology and regenerative medicine. As the life sciences sector increasingly shifts toward personalised, cell-based therapies, the demand for non-invasive, real-time monitoring tools will only intensify. Our HoloMonitor® platform, built on Quantitative Phase Imaging (QPI), is uniquely suited to meet this need, offering a label-free, interference-free method for long-term cell tracking and analysis.
In the upcoming fiscal year, we will focus on four core areas:
- Clinical Integration: Deepening partnerships with clinical research centres and regulatory bodies to validate and certify our systems for clinical use.
- Product Innovation: Continuing development of the HoloMonitor® system, including AI-driven features that enhance automation and data interpretation.
- Global Reach: Expanding our market presence, particularly in North America and Asia, where regenerative medicine is gaining momentum.
- Commercial Control: Reclaiming full responsibility for global sales and marketing to ensure a consistent and responsive market approach.
We are also strengthening our alliances with leading institutions such as the Wake Forest Institute for Regenerative Medicine (WFIRM), which will play a key role in accelerating our clinical ambitions. These collaborations and strategic clarity position PHI to lead in the transformation of live cell analysis and regenerative medicine.
As I since May resumed leadership of PHI, I have done so with a renewed sense of purpose and optimism. Together, we are shaping a future where scientists and clinicians can interact with living cells in ways that were previously unimaginable.
Patrik Eschricht, CEO
Medicinteknikbolaget Phase Holographic redovisar minskad omsättning under första kvartalet jämfört med samma period året innan. Rörelseförlusten ökade.
Omsättningen sjönk till 0,4 miljoner kronor (1,4).
Ebitda-resultatet blev -7,0 miljoner kronor (-4,7).
Rörelseresultatet blev -8,8 miljoner kronor (-5,9).
Resultatet före och efter skatt var -8,5 miljoner kronor (-5,9).
Resultat per aktie uppgick till -0,14 kronor (-0,23).
"PHI har en strategisk position vid skärningspunkten mellan bildteknik och regenerativ medicin. I takt med att life science-sektorn i allt högre grad övergår till personaliserade, cellbaserade terapier kommer efterfrågan på icke-invasiva verktyg för realtidsövervakning att öka. Vår Holomonitor-plattform, som bygger på kvantitativ fasavbildning (QPI), är unik för att möta detta behov och erbjuder en märkningsfri, störningsfri metod för långsiktig cellspårning och analys", skriver vd Patrik Eschricht.
Phase Holographic, Mkr | Q1-2025/2026 | Q1-2024/2025 | Förändring |
Nettoomsättning | 0,4 | 1,4 | -71,4% |
Ebitda | -7,0 | -4,7 | |
Rörelseresultat | -8,8 | -5,9 | |
Resultat före skatt | -8,5 | -5,9 | |
Nettoresultat | -8,5 | -5,9 | |
Resultat per aktie, kronor | -0,14 | -0,23 | |
Min kommentar
En skräprapport som jag trodde. Man ids inte leta efter ljuspunkter. Ska möjligtvis vara den här texten från årsredovisningen : Klinisk cellterapi håller på att bli en industri och PHI står i centrum för denna omvandling. Det är inte längre ett teknikföretag som väntar på sin marknad. Det är marknaden som börjar komma ikapp. För dem som ser den större bilden är tålamod inte en kostnad, det är en tillgång. Och nu är det på väg att löna sig. /
Njae,nu är det dax att börja leverera tycker jag. Tålamodet börjar tryta.
Mvh the99